European Parliament vote could deter investors from medical device technology
This article was originally published in Clinica
Executive Summary
The regulatory costs for devices that would be hit by the European Parliament's vote to favour the primacy of pharmaceutical legislation over other legislation where there are cases of doubt could be "multiplied drastically". That is the fear of the European medical device industry association, Eucomed, which predicts a negative impact on the pace of development and the consequent downturn on investment in Europe in medical technology manufacturing. That is unless the European Parliament's vote is overturned by the European Council which is due to complete the final reading of the text early in 2004.